Actively Recruiting
PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation
Led by University Hospital, Lille · Updated on 2026-04-22
750
Participants Needed
1
Research Sites
415 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood. The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation. The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.
CONDITIONS
Official Title
PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient undergoing atrial fibrillation catheter ablation
- Able to give their consent
You will not qualify if you...
- Children
- Patient under guardianship
- Patients unable to give their consent
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut Coeur-Poumon, CHU
Lille, France
Actively Recruiting
Research Team
S
Sandro Ninni, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here